Safety profile of grepafloxacin compared with other fluoroquinolones

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue SUPPL. A, 1997, Pages 83-92

  Stahlmann, Ralf ^a   Schwabe, Rudolf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CEFIXIME; CIPROFLOXACIN; DOXYCYCLINE; FENBUFEN; GREPAFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICULAR CARTILAGE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DOG; DRUG BLOOD LEVEL; DRUG SAFETY; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; INSOMNIA; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIZATION; RABBIT; RASH; TASTE DISORDER; VOMITING;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG EVALUATION; FLUOROQUINOLONES; HUMANS; PIPERAZINES; QUINOLONES;

EID: 0031460979     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.suppl_1.83     Document Type: Conference Paper

References (44)

1. Christ, W., Lehnert, T. & Ulbrich, B. (1988). Specific toxicologic aspects of the quinolones. Reviews of Infectious Diseases 10, Suppl. 1, S141-6.
2. Stahlmann, R. & Lode, H. (1988). Safety overview: toxicity, adverse effects and drug interactions. In The Quinolones (Andriole, V. T., Ed.), pp. 201-33. Academic Press, London.
3. Stahlmann, R. (1990). Safety profile of the quinolones. Journal of Antimicrobial Chemotherapy 26, Suppl. D, 31-44.
4. Hooper, D. C. & Wolfson, J. S. (1993). Adverse effects. In Quinolone Antimicrobial Agents, 2nd edn (Hooper, D. C. & Wolfson J. S., Eds), pp. 489-512. American Society for Microbiology, Washington, DC.
5. Norrby, S. R. & Lietman, P. S. (1993). Safety and tolerability of fluoroquinolones. Drugs 45, Suppl. 3, 59-64.
6. Domagala, J. M. (1994). Structure-activity and structure-side-effect relationship for the quinolone antibacterials. Journal of Antimicrobial Chemotherapy 33, 685-706.
7. Christ, W. & Esch, B. (1994). Adverse reactions to fluoroquinolones in adults and children. Infectious Diseases in Clinical Practice 3, Suppl 3, S168-76.
8. Takayama, S., Hirohashi, M., Kato, M. & Shimada, H. (1995). Toxicity of quinolone antimicrobial agents. Journal of Toxicology and Environmental Health 45, 1-45.
9. Anon. (1996). Grepafloxacin Clinical Investigators' Brochure. GlaxoWellcome Research and Development, Greenford, UK.
10. Lode, H. & Stahlmann, R. (1990) Evaluation of safety and tolerance in clinical trials with antimicrobial agents. European Journal of Clinical Microbiology and Infectious Diseases 9, 530-3.
11. Wolfson, J. S. & Hooper, D. C. (1991). Overview of fluoroquinolone safety. American Journal of Medicine 91, Suppl. 6A, 153S-161S.
12. Brauner, G. J. (1975). Bullous photoreaction to nalidixic acid. American Journal of Medicine 58, 576-80.
13. Bowie, W. R., Willetts, V. & Jewesson, P. J. (1989). Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. Antimicrobial Agents and Chemotherapy 33, 1778-82.
14. Burdge, D. R., Nakielna, E. M. & Rabin, H. R. (1995). Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 39, 793.
15. Williams, P. D. & Helton, D. R. (1991). The proconvulsive activity of quinolone antibiotics in an animal model. Toxicology Letters 58, 23-8.
16. Nakamura. M., Abe, S., Goto, Y., Chishaki, A., Akazawa, K. & Kato, M. (1994) In vivo assessment of prevention of white-noise-induced seizure in magnesium-deficient rats by N-methyl-D-aspartate receptor blockers. Epilepsy Research 17, 249-56.
17. Macallum, E., Houston, B. & Smith, G. (1993). Subchronic toxicity of a quinolone antibacterial agent in beagle dogs. Toxicologist 13, 377 (Abstract 1473).
18. Stahlmann, R., Vormann, J., Günther, T., Förster, C., Zippel, U., Lozo, E. et al. (1997). Effects of quinolones, magnesium deficiency or zinc deficiency on joint cartilage in rats. Magnesium Bulletin, 19, 7-22.
19. Stahlmann, R., Bankenburg, G. & Neubert, D. (1988). Studies on cartilage formation and differentiation in limb bud culture in the presence of nalidixic acid, ofloxacin, and ciprofloxacin. Reviews of Infectious Disease 10, Suppl.1, S147-S149.
20. Kociok, K., Lozo, E., Förster, C., Dalsenter, P., Kastner, U., Vormann, J. et al. (1996). Chondrotoxicity of ofloxacin in immature rats is not detectable with a segment III-type study. Teratology 53, 32A (Abstract P33).
21. Gough, A. W., Kasali, O. B., Sigler, R. E. & Baragi, V. (1992). Quinolone arthropathy - acute toxicity to immature articular cartilage. Toxicologic Pathology 20, 436-50.
22. Stahlmann, R., Förster, C. & Van Sickle, D. (1993). Quinolones in children: are concerns over arthropathy justified? Drug Safety 9, 397-403.
23. Förster, C., Kociok, K., Shakibaei, M., Merker, H. J., Vormann, J., Günther, T. et al. (1996). Integrins on joint cartilage chondrocytes and alterations by ofloxacin magnesium deficiency in immature rats. Archives of Toxicology 70, 261-70.
24. Förster, C., Kociok, K., Shakibaei, M., Merker, H. J. & Stahlmann, R. (1996). Quinolone-induced cartilage lesions are not reversible in rats. Archives of Toxicology 70, 474-81.
25. Förster, C., Zippel, U., Lozo, E., Vormann, J., Merker, H. J. & Stahlmann, R. (1996). Effects of quinolones on joint cartilage in juvenile rats and other animals: focus on mechanistic aspects. Chemotherapy Journal 5, Suppl. 13, 6-13.
26. Adam, D. (1996). Quinolones in pediatrics: pros and cons. Chemotherapy Journal 5, Suppl. 13, 37-40.
27. Pertuiset, E., Lenoir, G., Jehanne, M., Douchan F., Guillot, M. & Menkes, C. J. (1989). Tolerance articulaire de la pefloxacine et de l'ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Revue de Rheumatisme 56, 735-40.
28. Hampel, B., Hullmann, R. & Schmidt, H. (1997). Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use - safety report. Pediatric Infectious Disease Journal 16, 127-9.
29. Schaad, U. B., Wedgwood, J., Ruedeberg, A., Kraemer, R. & Hampel, B. (1997). Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatric Infectious Disease Journal 16, 106-1.
30. Stahlmann, R., Merker, H, J., Hinz, N., Chahoud, I., Webb, J., Heger, W. et al. (1990) Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Archives of Toxicology 64, 193-204.
31. Bethell, D. B., Day, N. P. J., Dung, N. M., McMullin, C., Loan, H. T., Tam, D. T. H. et al. (1996). Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrobial Agents and Chemotherapy 40, 2167-72.
32. Stahlmann, R., Förster, C., Shakibaei, M., Vormann, J., Günther, T. & Merker, H. J. (1995). Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy. Antimicrobial Agents and Chemotherapy 39, 2013-8.
33. Vormann, J., Förster, C., Zippel, U., Lozo, E., Günther, T., Merker, H. J. et al. (1997). Effects of magnesium deficiency on magnesium and calcium content in bone and cartilage in developing rats in correlation to chondrotoxicity. Calcified Tissue International, in press.
34. Burkhardt, J. E., Hill, M. A., Carlton, W. W. & Kesterson, J. W. (1990). Histologic and histochemical changes in articular cartilages of immature Beagle dogs dosed with difloxacin, a fluoroquinolone. Veterinary Pathology 27, 162-70.
35. Syllm-Rapoport, I., Strassburger, I., Grüneberg, D. & Zirbel, C. (1958). Über den experimentellen Magnesium-Mangel beim Hund. Acta Biologica et Medica Germanica 1, 141-63.
36. Hayem, G., Petit, P. X., Levacher, M., Gaudin, C., Kahn, M. F. & Pocidalo, J. J. (1994). Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrobial Agents and Chemotherapy 38, 243-7.
37. Schwabe, R., Zippel, U., Förster, C., Baumann-Wilschke, I. & Stahlmann, R. (1996). Plasma concentrations and chondrotoxicity of three fluoroquinolones in juvenile rats. Naunyn Schmiedeberg's Archives of Pharmacology 354, Suppl. 1, Abstract 110.
38. Höffken, G. K., Borner, K., Glatzel, P. D., Köeppe, P. & Lode, H. (1985) Reduced enterai absorption of ciprofloxacin in the presence of antacids. European Journal of Clinical Microbiology and Infectious Diseases 4, 345.
39. Lode, H. (1988). Drug interactions with quinolones. Reviews of Infectious Diseases 10, Suppl. 1, 132-6.
40. Lomaestro, B. M. & Bailie, G. R. (1991). Quinolone-cation interactions: a review. DICP Annals of Pharmacotherapy 25, 1249-58.
41. Ross, D. & Riley, R. (1993) Physicochemical properties of the fluoroquinolone antimicrobials. V. Effect of fluoroquinolone structure and pH on the complexation of various fluoroquinolones with magnesium and calcium ions. International Journal of Pharmaceutics 93, 121-9.
42. Lecomte, S., Baron, M. H., Chenon. M. T., Coupry, C. & Moreau, N. J. (1994). Effect of magnesium complexation by fluoroquinolones on their antibacterial properties. Antimicrobial Agents and Chemotherapy 38, 2810-6.
43. Kawai, Y., Matsubayashi, K. & Hakusui, H. (1996). Interaction of quinolones with metal cations in aqueous solution. Chemical and Pharmaceutical Bulletin 44, 1425-30.
44. Niki, Y., Hashiguchi, K., Okimoto, N. & Soejima, R. (1992). Quinolone antimicrobial agents and theophylline. Chest 101, 881.